Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

Monitoring Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy

Primary Objective:

- Evaluate tumor cell free (cf)DNA as a dynamic marker of response to immuno-oncology (IO) therapy

Exploratory Objective:

- Collect data on somatic mutations in cfDNA to gain insight into the biology of IO-responders and -non-responders

Inclusion Criteria:

• Renal Cell Carcinoma with clear cell component
• Stage IV
• Receiving IO-containing regimen
• Measurable disease per RECIST 1.1

Exclusion Criteria:

• Active cancer (exclusion criteria only for healthy patient cohort)